Coenzyme Q 10 (CoQ 10 or ubiquinone) deficiency in humans is associated with clinically heterogeneous diseases. 1 Five major phenotypes have been described: (1) encephalomyopathy, (2) cerebellar ataxia, (3) infantile multisystemic form, (4) nephropathy, and (5) isolated myopathy ( Table 1) .
METHODS
Seventy-six patients with CoQ 10 deficiency (36 previously unreported) were studied at the H. Houston Merritt Clinical Research Center, Columbia University Medical Center, New York, New York, under the center's institutional review board's protocols. Coenzyme Q 10 levels were measured in muscle, cultured fibroblasts, and/or lymphoblasts. 8, 17 Coenzyme Q 10 levels reduced more than 2 standard deviations below mean control values were considered deficient. Patients with CoQ 10 levels decreased in 1 member of the family with similar phenotype and/or genetic mutation were considered to have CoQ 10 deficiency.
Dideoxy sequencing was performed on all exons and flanking intronic regions of genes involved in CoQ 10 biosynthesis, associated with secondary CoQ 10 deficiencies, or encoding proteins with similar function, structure, or both as proteins associated with CoQ 10 deficiency. In addition, we sequenced PSAP-encoding saposin B, a cytosolic protein that binds and transfers CoQ 10 , and POLG (eTable 1, http://www .archneurol.com).
CLINICAL FEATURES
Since the first description of human ubiquinone deficiency, 113 patients have been reported (Tables 1, 2 , and 3). Of 455 patients referred to our center for possible CoQ 10 deficiency from 1997 to 2010, 76 patients (64 families) had CoQ 10 deficiency, 40 of which were previously described. The reported patients and our 36 new patients composed 149 cases: 4 patients with encephalomyopathy, 14 with isolated myopathy, 17 with infantileonset multisystemic disease, 11 with nephropathy (with our without sensorineu-ral hearing loss), 94 with cerebellar ataxia, and 9 with atypical presentations.
Onset was predominantly in childhood (82% were aged Ͻ13 years) including 23% in infancy (aged Ͻ12 months). Onset during adolescence (7% were aged 13-18 years) and adulthood (11% were aged Ͼ18 years) were uncommon. The mortality rate was low (8%) and mainly seen in the infantile multisystemic and renal forms.
The encephalomyopathic form of CoQ 10 deficiency, manifesting as a triad of mitochondrial myopathy, recurrent myoglobinuria, and encephalopathy, has been reported in 4 patients (eTable 2). [2] [3] [4] Neurologic features included cerebellar ataxia, seizures, mental retardation, delayed motor development, progressive external ophthalmoplegia, and ptosis.
The myopathic form of CoQ 10 deficiency presents with muscle weakness, myoglobinuria, exercise intolerance, cramps, myalgia, and elevated creatine kinase. This condition has been described in 10 patients. [4] [5] [6] [7] We identified 4 additional patients (eTable 3).
Among the 17 patients (including 2 new patients) with the infantile multisystemic form, the combination of encephalopathy and nephropathy has been the most common presentation (eTable 4). [8] [9] [10] [11] [12] [13] [14] 33 Neurologic manifestations include psychomotor regression, ataxia, hypotonia, seizures, pyramidal syndrome, optic atrophy and retinopathy, deafness, and Leigh syndrome. The renal involvement is mainly nephrotic syndrome but occasionally tubulopathy. Three patients required kidney transplantation. 13, 15 In addition, liver, cardiac, and pancreatic involvement, as well as obesity have been described in literature and in our cohort. 10, 16, 33 Eleven patients (65%) died in early infancy, and causes of death were opportunistic infections, kidney failure, encephalopathy, or multi-organ failure.
Early-onset isolated steroid-resistant nephrotic syndrome owing to collapsing glomerulopathy and focal segmental glomerulosclerosis has been reported in 2 patients. 12 Moreover, the association between steroid-resistant nephrotic syndrome with sensorineural hearing loss has been described in patients with mutations in the CoQ 10 biosynthetic gene, COQ6; however, CoQ 10 level was not measured in these patients (eTable 5).
14 Cerebellar ataxia is the most common phenotype, with 94 patients (including 23 new patients) (eTable 6). [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Other manifestations include neuropathy, seizures, mental retardation, migraine, psychiatric disorders, muscle weakness and exercise intolerance, congenital hypotonia, upper motor neuron signs, dystonia and chorea, ptosis and ophthalmoplegia, retinitis pigmentosa, optic atrophy, oculomotor apraxia, deafness, lipomas, DandyWalker syndrome, agenesis of corpus callosum, hypogonadism and other endocrinological problems, hypoalbuminemia, and hypercholesterolemia.
Among the patients classified as atypical cases, there were 2 adult sisters with childhood-onset Leigh syndrome, growth retardation, infantilism, ataxia, deaf- Typically progresses rapidly with high mortality (9/17 = 53%)
Cerebellar ataxia [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] 94 ( ness, and lactic acidosis, 34 a 4-year-old girl with cardiofaciocutaneous syndrome, 35 2 unrelated patients with neonatal hypotonia and infantile spasm (1 reported), 36 2 sisters with adult-onset cerebellar ataxia and nephrotic syndrome, and a 16-year-old girl with onset at age 4 years of exercise intolerance, fatigue, recurrent headaches, short stature, deafness, retinopathy, and mental retardation. One new patient was the father of a child with cerebellar ataxia (P119 in eTable 6) who had mild creatine kinase elevation but normal examination and brain magnetic resonance imaging results.
DIAGNOSIS
Initial biochemical evaluation of patients with suspected CoQ 10 deficiency should include blood lactate measurement, although normal values do not exclude ubiquinone deficiency. Muscle biopsies occasionally show mitochondrial proliferation or lipid droplets, but they can be normal or show only nonspecific changes.
Reduced biochemical activities of respiratory chain complexes, in particular complexes IϩIII (nicotinamide adenine dinucleotide-cytochrome c oxidoreductase) and complexes IIϩIII (succinate-cytochrome c oxidoreductase) in muscle, suggest CoQ 10 deficiency, although activities of these enzymes may be normal particularly when the deficiency is mild. Reduction of these enzyme activities and deficiency of CoQ 10 in skin fibroblasts can be an important confirmation of ubiquinone deficiency; however, normal levels do not exclude deficiency in muscle. Direct measurement of CoQ 10 in skeletal muscle by high-performance liquid chromatography is the most reliable test for the diagnosis. In contrast, plasma concentrations of ubiquinone are significantly influenced by dietary uptake, therefore not reliable. Measurements of CoQ 10 in peripheral blood mononuclear cells has detected deficiency in a small number of patients; however, correlations with muscle CoQ 10 measurements in a larger cohort of patients will be necessary to assess clinical use of mononuclear cell ubiquinone levels.
Morphologic and biochemical findings differ in the various clinical forms. In patients with the encephalomyopathic, myopathic, or infantile multisystemic forms, muscle biopsies have typically revealed abnormal mitochondrial proliferation (ragged-red fibers or excessive succinate dehydrogenase histochemical activity) and lipid accumulation as well as reduced biochemical activities of respiratory chain enzyme complexes IϩIII and IIϩIII, while all muscle samples showed decreased CoQ 10 levels. In contrast, fibroblast CoQ 10 levels have varied and were normal in 1 patient with encephalomyopathy but low in 1 of 2 patients with the myopathic form and in 7 of 8 patients with the infantile multisystemic form.
In 2 patients with isolated nephropathy, CoQ 10 levels and respiratory chain enzyme activities were reduced in either fibroblasts or muscle. Ragged-red-like fibers were observed in the only patient who underwent muscle biopsy. 12 Muscle biopsies revealed mitochondrial proliferation, cytochrome c oxidase-negative fibers, or lipid accumulation in 15 of 49 patients and reduced respiratory chain enzyme activities in 27 of 51 patients with the ataxic form. Levels of CoQ 10 were low in muscle but reduced in 18 of 30 fibroblasts.
GENETICS
Primary CoQ 10 deficiency is due to mutations in genes involved in CoQ 10 biosynthesis (Figure) . Secondary deficiencies include diseases caused by mutations in genes unrelated to ubiquinone biosynthesis, for example, the aprataxin (APTX) gene causing ataxia and oculomotor apraxia, 20, 26, 27, 29 the electron-transferring-flavoprotein dehydrogenase gene (ETFDH) causing isolated myopathy, 7 and the BRAF gene causing cardiofaciocutaneous syndrome. 35 Moreover, CoQ 10 deficiency has been reported in association with mitochondrial DNA mutations. 1 In most cases, family history suggests autosomal recessive inheritance. Pathogenic mutations have been reported in 63 patients (Table 1) .
No mutations have been described among the encephalomyopathic patients. Except for the patients reported by Gempel and colleagues in 2007, 7 we did not find other mutations in ETFDH in our cohort of patients with isolated myopathy, indicating that other genes may be responsible for this phenotype.
Most patients with the infantile-onset multisystemic variant have genetically confirmed primary CoQ 10 deficiency. Mutations have been described in COQ2 (3 patients), 11, 12, 16 PDSS2 (1 patient),
8 COQ9 (1 patient), 9 PDSS1 (2 patients), 16 and COQ6 (3 patients).
14 Interestingly, 2 patients with isolated nephrotic syndrome had COQ2 mutations. 11, 12 Thus, patients with COQ2 mutations have presented with either infantile multisystemic syndrome or isolated nephropathy. There are 3 potential explanations for the divergent phenotypes. First, variations in the phenotypes may be due to genetic or environmental modifiers. Second, patients with isolated nephropathies may develop multisystemic disease later in life. Third, CoQ 10 treatment may have altered the clinical course of the disease by preventing neurologic complications in both patients with only renal disease. In contrast, in 9 patients, mutations in the COQ6 gene have been associated with kidney involvement (nephrotic syndrome and nephrolithiasis) and sensorineural hearing loss. 14 A subgroup of patients with juvenile-onset cerebellar ataxia have primary CoQ 10 deficiency owing to mutations in the ADCK3 gene (22 patients). 17, 24, 28, [30] [31] [32] Secondary forms have been described in association with mutations in the APTX gene (12 patients) including 4 affected members of 1 family that we studied. 20, 26, 27, 29 Most patients with cerebellar ataxia and CoQ 10 deficiency still lack molecular diagnosis.
THERAPY
Patients with CoQ 10 deficiency showed variable responses to CoQ 10 treatment (Table 3) . We recommend oral supplementation doses up to 2400 mg daily in adult patients and up to 30 mg/kg daily in pediatric patients, divided into 3 doses per day.
In patients with encephalomyopathy, muscle symptoms improved after therapy. [2] [3] [4] In 1 of our patients, muscle symptoms and seizures resolved, creatine kinase and lactic acid levels normalized, and a muscle biopsy showed CoQ 10 level normalization. 4 In contrast, another patient developed cerebellar ataxia. 3 Six patients with pure myopathy [4] [5] [6] [7] (including 1 unreported) improved after CoQ 10 supplementation, while 2 patients with ETFDH mutations improved only after addition of treatment with riboflavin, 100 mg daily. 7 In some patients with the infantile multisystemic form, CoQ 10 supplementation has halted progression of the encephalopathy and improved the myopathy. 15 One patient with a homozygous COQ2 mutation during therapy showed neurologic but not renal improvement and underwent kidney transplant; however, his sister with isolated nephropathy received CoQ 10 and has had progressive recovery of renal function, reduced proteinuria, and no neurologic manifestations. [11] [12] [13] In contrast, a patient with a homozygous COQ9 mutation during therapy had a reduction of blood lactate but neurologic and cardiac worsening and died at age 2 years. 9 Similarly, despite treatment, a patient with PDSS2 mutations developed intractable seizures and died at age 8 months, 8 and a patient with infantile-onset Leigh syndrome, hepatopathy, and hypertrophic cardiomyopathy after initial clinical improvement died at age 3 years. Published data for 2 patients with mutations in the COQ6 gene noted decreased proteinuria in both patients after CoQ 10 treatment, but hearing improved in only 1 patient. 14 Response to CoQ 10 supplementation in patients with cerebellar ataxia is also variable. Three patients with mutations in the ADCK3 gene showed mild clinical improvement after treatment, 17,30,31 but 7 patients carrying mutations in the same gene did not improve 24, 32 and another patient, despite dramatic muscle improvement, developed tremor, myoclonic jerks, and cerebellar atrophy. 23, 24 In 3 siblings with mutations in the APTX gene, CoQ 10 supplementation was associated with clear improved ambulation as well as resolution of seizures in 1 patient. 20 Nevertheless, another patient with APTX mutations did not improve after therapy. 27 Improvement in muscle but not neurologic signs and symptoms has been noted in 1 new and 2 reported patients. 18, 19 Reductions in International Cooperative Rating Scale scores in 9 patients with an unknown genetic defect and in 1 patient with ADCK3 gene mutations have been documented. 22, 25, 30 Eleven patients with undefined molecular defect did not respond to therapy. 21, 31 Among the clinically atypical cases of CoQ 10 deficiency, 2 sisters with Leigh syndrome and 1 patient with cardiofaciocutaneous syndrome improved after CoQ 10 supplementation. 34, 35 One patient with neonatal hypotonia and infantile spasm showed no improvement. 36 
CONCLUSIONS
It is important to identify CoQ 10 deficiency as this condition often responds to supplementation. The diagnosis can be made by direct measurement of CoQ 10 in muscle and reinforced by the presence of reduced biochemical activities of respiratory chain complexes, in particular complexes IϩIII and IIϩIII. Molecular genetic testing has revealed causative mutations in a small proportion of patients, indicating that screening for DNA mutations is not yet effective for diagnosing CoQ 10 deficiency. Our observations not only highlight the clinical heterogeneity of CoQ 10 deficiency but also the genetic heterogeneity that is likely related to the large number of proteins involved in ubiquinone biosynthesis and regulation and of secondary CoQ 10 deficiencies. Clinical improvement after CoQ 10 supplementation was documented in many patients, but treatment protocols have not been standardized and results have not been uniform. Progress in our knowledge of the genetic bases of CoQ 10 deficiencies may help researchers develop a more accurate molecular classification of this syndrome, while additional studies of the pathogenesis of CoQ 10 deficiency may lead to more effective therapies.
